• 1
    Garcia-Tsao G, Groszmann RJ, Fisher RL, Conn HO, Atterbury CE, Glickman M. Portal pressure, presence of gastroesophageal varices and variceal bleeding. Hepatology 1985; 5: 41924.
  • 2
    Lebrec D, De Fleury P, Rueff B, Nahum H, Benhamou JP. Portal hypertension, size of esophageal varices, and risk of gastrointestinal bleeding in alcoholic cirrhosis. Gastroenterology 1980; 79: 113944.
  • 3
    Morali GA, Sniderman KW, Deitel KM, et al. Is sinusoidal portal hypertension a necessary factor for the development of hepatic ascites? J Hepatol 1992; 16: 24950.
  • 4
    Braillon A, Cales P, Valla D, Gaudy D, Geoffroy P, Lebrec D. Influence of the degree of liver failure on systemic and splanchnic haemodynamics and on response to propranolol in patients with cirrhosis. Gut 1986; 27: 12049.
  • 5
    Dib N, Konate A, Oberti F, Cales P. Non-invasive diagnosis of portal hypertension in cirrhosis Application to the primary prevention of varices. Gastroenterol Clin Biol 2005; 29: 97587.
  • 6
    Gressner AM, Tittor W. Serum laminin–its concentration increases with portal hypertension in cirrhotic liver disease. Klin Wochenschr 1986; 64: 12408.
  • 7
    Gressner AM, Kropf J. Concentration of laminin in serum related to the degree of esophageal varices in fibrotic liver diseases. Clin Chem 1988; 34: 10056.
  • 8
    Gressner AM, Tittor W, Negwer A. Serum concentrations of N-terminal propeptide of type III procollagen and laminin in the outflow of fibrotic livers compared with liver-distal regions. Hepatogastroenterology 1986; 33: 1915.
  • 9
    Gressner AM, Tittor W, Negwer A, Pick-Kober KH. Serum concentrations of laminin and aminoterminal propeptide of type III procollagen in relation to the portal venous pressure of fibrotic liver diseases. Clin Chim Acta 1986; 161: 24958.
  • 10
    Korner T, Kropf J, Gressner AM. Serum laminin and hyaluronan in liver cirrhosis: markers of progression with high prognostic value. J Hepatol 1996; 25: 6848.
  • 11
    Kropf J, Gressner AM, Tittor W. Logistic-regression model for assessing portal hypertension by measuring hyaluronic acid (hyaluronan) and laminin in serum. Clin Chem 1991; 37: 305.
  • 12
    Kondo M, Miszputen SJ, Leite-mor MM, Parise ER. The predictive value of serum laminin for the risk of variceal bleeding related to portal pressure levels. Hepatogastroenterology 1995; 42: 5425.
  • 13
    Gressner AM, Tittor W, Kropf J. The predictive value of serum laminin for portal hypertension in chronic liver diseases. Hepatogastroenterology 1988; 35: 95100.
  • 14
    Mal F, Hartmann DJ, Trinchet JC, Lacombe F, Ville G, Beaugrand M. Serum laminin and portal pressure in alcoholic cirrhosis A study of 39 patients. Gastroenterol Clin Biol 1988; 12: 8414.
  • 15
    Valla D, Bercoff E, Menu Y, Bataille C, Lebrec D. Discrepancy between wedged hepatic venous pressure and portal venous pressure after acute propranolol administration in patients with alcoholic cirrhosis. Gastroenterology 1984; 86: 14003.
  • 16
    The French METAVIR Cooperative Study Group. Intraobserver and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C. Hepatology 1994; 20: 1520.
  • 17
    Imbert-Bismut F, Messous D, Thibault V, et al. Intra-laboratory analytical variability of biochemical markers of fibrosis (Fibrotest) and activity (Actitest) and reference ranges in healthy blood donors. Clin Chem Lab Med 2004; 42: 32333.
  • 18
    Imbert-Bismut F, Ratziu V, Pieroni L, Charlotte F, Benhamou Y, Poynard T. Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study. Lancet 2001; 357: 106975.
  • 19
    Poynard T, Imbert-Bismut F, Ratziu V, et al. Biochemical markers of liver fibrosis in patients infected by hepatitis C virus: longitudinal validation in a randomized trial. J Viral Hepat 2002; 9: 12833.
  • 20
    Poynard T, Imbert-Bismut F, Munteanu M, et al. Overview of the diagnostic value of biochemical markers of liver fibrosis (FibroTest, HCV FibroSure) and necrosis (ActiTest) in patients with chronic hepatitis C. Comp Hepatol 2004; 3: 8.
  • 21
    Ngo Y, Munteanu M, Messous D. et al. A prospective analysis of the prognostic value of biomarkers (FibroTest) in patients with chronic hepatitis C. Clin Chem 2006; 52: 188796.
  • 22
    DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics 1988; 44: 83745.
  • 23
    Zhou X, Obuchowski N, McClish D. Statistical Methods in Diagnostic Medicine. New York: Wiley, 2002.
  • 24
    Huet PM, Pomier-Layrargues G. The hepatic venous pressure gradient: “remixed and revisited”. Hepatology 2004; 39: 2958.
  • 25
    Groszmann RJ, Wongcharatrawee S. The hepatic venous pressure gradient: anything worth doing should be done right. Hepatology 2004; 39: 2802.
  • 26
    Chalasani N, Imperiale TF, Ismail A, et al. Predictors of large esophageal varices in patients with cirrhosis. Am J Gastroenterol 1999; 94: 328591.
    Direct Link:
  • 27
    Giannini E, Botta F, Borro P, et al. Platelet count/spleen diameter ratio: proposal and validation of a non-invasive parameter to predict the presence of oesophageal varices in patients with liver cirrhosis. Gut 2003; 52: 12005.
  • 28
    Madhotra R, Mulcahy HE, Willner I, Reuben A. Prediction of esophageal varices in patients with cirrhosis. J Clin Gastroenterol 2002; 34: 815.
  • 29
    Ng FH, Wong SY, Loo CK, Lam KM, Lai CW, Cheng CS. Prediction of oesophagogastric varices in patients with liver cirrhosis. J Gastroenterol Hepatol 1999; 14: 78590.
  • 30
    Pilette C, Oberti F, Aube C, et al. Non-invasive diagnosis of esophageal varices in chronic liver diseases. J Hepatol 1999; 31: 86773.
  • 31
    Schepis F, Camma C, Niceforo D, et al. Which patients with cirrhosis should undergo endoscopic screening for esophageal varices detection? Hepatology 2001; 33: 3338.
  • 32
    Thomopoulos KC, Labropoulou-Karatza C, Mimidis KP, Katsakoulis EC, Iconomou G, Nikolopoulou VN. Non-invasive predictors of the presence of large oesophageal varices in patients with cirrhosis. Dig Liver Dis 2003; 35: 4738.
  • 33
    Zaman A, Becker T, Lapidus J, Benner K. Risk factors for the presence of varices in cirrhotic patients without a history of variceal hemorrhage. Arch Intern Med 2001; 161: 256470.
  • 34
    Oberti F, Pilette C, Rifflet H, et al. Effects of simvastatin, pentoxifylline and spironolactone on hepatic fibrosis and portal hypertension in rats with bile duct ligation. J Hepatol 1997; 26: 136371.
  • 35
    Consigny Y, Plessier A, Gervais A, Cazals-Hatem D, Degott C, Moreau R. The hepatic venous pressure gradient in patients with chronic hepatitis C is only associated with the extent of fibrosis and the severity of liver failure. J Hepatol 2003; 38(Suppl. 2): 134 [Abstract].
  • 36
    Nagula S, Jain D, Groszmann RJ, Garcia- Tsao G. Histological-hemodynamic correlation in cirrhosis-a histological classification of the severity of cirrhosis. J Hepatol 2006; 44: 1117.
  • 37
    Bahr MJ, Boker KH, Horn W, Gunzler V, Manns MP. Serum laminin P1 levels do not reflect critically elevated portal pressure in patients with liver cirrhosis. Hepatogastroenterology 1997; 44: 12005.
  • 38
    Diaz F, Collazos J, Genolla J. Serum laminin levels offer only a little additional information in liver disease. J Clin Gastroenterol 1994; 18: 1147.
  • 39
    Poynard T, Munteanu M, Imbert-Bismut F, et al. Prospective analysis of discordant results between biochemical markers and biopsy in patients with chronic hepatitis C. Clin Chem 2004; 50: 134455.
  • 40
    Thabut D, Trabut J, Massard J, Rudler M, Munteanu M, Messous D. Non invasive diagnosis of large oesophageal varices with Fibrotest in patients with cirrhosis: a preliminary retrospective study. Liver Int 2006; 26: 2719.
  • 41
    Sarin SK, Sethi KK, Nanda R. Measurement and correlation of wedged hepatic, intrahepatic, intrasplenic and intravariceal pressures in patients with cirrhosis of liver and non-cirrhotic portal fibrosis. Gut 1987; 28: 2606.
  • 42
    Thabut D, Naveau S, Charlotte F, et al. The diagnostic value of biomarkers (AshTest) for the prediction of alcoholic steato-hepatitis in patients with chronic alcoholic liver disease. J Hepatol 2006; 44: 117585.
  • 43
    Groszmann RJ, Garcia-Tsao G, Bosch J, et al. Beta-blockers to prevent gastroesophageal varices in patients with cirrhosis. N Engl J Med 2005; 353: 225461.
  • 44
    Alexandrakis MG, Moschandrea J, Kyriakou DS, Alexandraki R, Kouroumalis E. Use of a variety of biological parameters in distinguishing cirrhotic from malignant ascites. Int J Biol Markers 2001; 16: 459.
  • 45
    Bureau C, Metivier S, Peron J, et al. Prospective assessment of liver stiffness for the non-invasive diagnosis of portal hypertension. Hepatology 2006; 44(Suppl. 1): 467A.
  • 46
    Lemoine M, Katsahian S, Nahon P, et al. Liver stiffness measurement is correlated with hepatic venous pressure gradient in patients with uncomplicated alcoholic and/or HCV related cirrhosis. Hepatology 2006; 44(Suppl. 1): 42A.